DMS Imaging (XBRU:ALIMG) Inventories, Finished Goods : €0.79 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is DMS Imaging Inventories, Finished Goods?

DMS Imaging's quarterly finished goods declined from Dec. 2022 (€0.61 Mil) to Jun. 2023 (€0.44 Mil) but then increased from Jun. 2023 (€0.44 Mil) to Dec. 2023 (€0.79 Mil).

DMS Imaging's annual finished goods declined from Dec. 2021 (€1.08 Mil) to Dec. 2022 (€0.61 Mil) but then increased from Dec. 2022 (€0.61 Mil) to Dec. 2023 (€0.79 Mil).

DMS Imaging Inventories, Finished Goods Historical Data

The historical data trend for DMS Imaging's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMS Imaging Inventories, Finished Goods Chart

DMS Imaging Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Finished Goods

Get a 7-Day Free Trial

1.08

0.61

0.79

DMS Imaging Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Inventories, Finished Goods	Get a 7-Day Free Trial															1.08	0.66	0.61	0.44	0.79

DMS Imaging Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

DMS Imaging (XBRU:ALIMG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DMS Imaging SA (XBRU:ALIMG) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

AS0:Germany

Address

7 Rue des Chasseurs Ardennais, Liege, BEL, 4031

Website

https://www.dms-imaging.com

DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.

DMS Imaging (XBRU:ALIMG) Headlines

No Headlines